Literature DB >> 17213462

Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway.

Yuichiro Izumi1, Yushi Nakayama, Tomohiko Mori, Hiroki Miyazaki, Hideki Inoue, Yukimasa Kohda, Takeaki Inoue, Hiroshi Nonoguchi, Kimio Tomita.   

Abstract

Vasopressin V(1a) and V(2) receptors (V(1a)R and V(2)R, respectively) distribute in the collecting duct of the kidney. Although the function of V(2)R mediating the antidiuretic effect of AVP has been investigated in detail, the role of V(1a)R in the collecting ducts has not been elucidated. In the present study, we have investigated the role of the V(1a)R pathway in V(2)R promoter activity. We cloned the 5'-flanking region of rat V(2)R (rV(2)R) and investigated rV(2)R promoter activity in the LLC-PK(1) cell line transfected to express rat V(1a)R (rV(1a)R) dominantly (LLC-PK(1)/rV(1a)R). AVP induced a transient increase, followed by a sustained decrease, of rV(2)R promoter activity in these cells. This AVP-induced decrease of rV(2)R promoter activity was inhibited by V(1a)R, but not V(2)R, antagonist. PMA mimicked this decrease of rV(2)R promoter activity. On the contrary, 8-(4-chlorophenylthio)-cAMP increased rV(2)R promoter activity. These PMA- and 8-(4-chlorophenylthio)-cAMP-induced effects were not observed on the deletion segment of the 5'-flanking region lacking CAAT and SP1 sites. In conclusion, 1) expression of the V(2)R is downregulated via the V(1a)R pathway in LLC-PK(1)/rV(1a)R cells, and 2) expression of the V(2)R is downregulated by the PMA-induced PKC pathway and upregulated by the cAMP-PKA pathway. These opposite effects of PKC and PKA appear to be regulated by the same promoter region of CAAT and SP1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17213462     DOI: 10.1152/ajprenal.00358.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  7 in total

Review 1.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Heterologous downregulation of vasopressin type 2 receptor is induced by transferrin.

Authors:  Richard Bouley; Paula Nunes; Billy Andriopoulos; Margaret McLaughlin; Matthew J Webber; Herbert Y Lin; Jodie L Babitt; Thomas J Gardella; Dennis A Ausiello; Dennis Brown
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-12

3.  Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Debbie Zittema; Irina B Versteeg; Ron T Gansevoort; Harry van Goor; Emile de Heer; Kimberley A M Veraar; Dorien J M Peters; Esther Meijer
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 3.754

4.  Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.

Authors:  Julie Perucca; Daniel G Bichet; Pascale Bardoux; Nadine Bouby; Lise Bankir
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

Review 5.  Vasopressin antagonists in polycystic kidney disease.

Authors:  Vicente E Torres
Journal:  Semin Nephrol       Date:  2008-05       Impact factor: 5.299

Review 6.  Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation.

Authors:  Ewa Szczepanska-Sadowska; Agnieszka Wsol; Agnieszka Cudnoch-Jedrzejewska; Tymoteusz Żera
Journal:  Int J Mol Sci       Date:  2021-10-24       Impact factor: 5.923

7.  Effects of atrial natriuretic peptide on bicarbonate transport in long- and short-looped medullary thick ascending limbs of rats.

Authors:  Hiroshi Nonoguchi; Yuichiro Izumi; Yushi Nakayama; Takanobu Matsuzaki; Yukiko Yasuoka; Takeaki Inoue; Hideki Inoue; Tomohiko Mouri; Katsumasa Kawahara; Hideyuki Saito; Kimio Tomita
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.